A soon-to-be published guideline from the ACR and the Vasculitis Foundation on Kawasaki disease underscores the importance of early diagnosis and intensified treatment for people with this serious condition.1 Intravenous immunoglobulin (IVIG) remains the treatment mainstay, and prompt, aggressive treatment may be able to reduce the risk of serious complications in some patients. The guideline…
Search results for: giant cell arteritis
Does Switching from IV to Subcutaneous Tocilizumab Affect RA Disease Flare?
Researcher identified multiple factors for flare, including non-use of methotrexate, in patients with rheumatoid arthritis who had switched from intravenous (IV) tocilizumab to subcutaneous tocilizumab.
Tocilizumab Effective for Early SSc-Associated Interstitial Lung Disease
Treatment with tocilizimab preserved lung function in patients with systemic sclerosis (SSc) and interstitial lung disease (ILD) regardless of a patient’s level of lung involvement, according to a recent study.
Vasculitis Guidelines in Focus, Part 3: EGPA
In this third article in the series, we talk with Philip Seo, MD, MHS, about eosinophilic granulomatosis with polyangiitis (EGPA).
Vasculitis Guidelines in Focus, Part 2: ANCA-Associated Vasculitis
Sharon Chung, MD, MAS, discusses specific recommendations for the treatment and management of ANCA-associated vasculitis from the latest ACR Guideline.
Vasculitis Guidelines in Focus, Part 1: The Guideline Project
Sharon A. Chung, MD, MAS, director of the vasculitis clinic at the University of California, San Francisco, served as the principal investigator of the overall vasculitis guideline effort and talks about the process here.
FDA’s Arthritis Advisory Committee Narrowly Endorses Avacopan Approval
On May 6, the U.S. Food & Drug Administration’s (FDA’s) Arthritis Advisory Committee narrowly voted in support of avacopan, a C5a receptor inhibitor, for the treatment of adult patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Although the panelists were excited about the possibility of a steroid-sparing therapy, some raised questions about whether results from…
Efficacy of Tocilizumab Monotherapy After Ultra-Short Glucocorticoid Administration in GCA
In a small study, patients with GCA maintained remission after receiving three days of treatment with methylprednisolone followed by tocilizumab.
Tocilizumab After Ultra-Short Course Steroids Promising for Newly Diagnosed GCA
NEW YORK (Reuters Health)—Tocilizumab induced a slow and lasting remission after an ultra-short pulse (three days) of steroids in newly diagnosed giant cell arteritis (GCA) patients, a proof-of-concept trial shows.1 His early research on cytokines and glucocorticoids led Peter Villiger, MD, of Medical Center Monbijou, Bern, Switzerland, to find ways to reduce steroid use, he…
3 Educators Offer Lessons Learned on Rheumatology Training
Leslie Kahl, MD, on Coaching I have been an academic clinician-educator for my entire career and, like most of my colleagues, have been called upon to advise, mentor and coach countless trainees and junior faculty members. Unlike most clinician-educators, though, I also served as associate dean for student affairs at Washington University School of Medicine,…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 17
- Next Page »